FBLG · FibroBiologics, Inc.
$0.84
-0.01 (-0.60%)
At close · Jul 17
Going-concern doubt
— flagged Apr 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Apr 30, 2026
Market Cap
$4.35M
Shares
5,208,915
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$18.65M
-67.1%
FY2025
Diluted EPS
-$8.40
-23.5%
FY2025
Operating Cash Flow
-$16.39M
-37.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $8.58M | $7.41M | $4.5M | $2.37M | |
| $8.61M | $9.24M | $9.23M | $6.52M | |
| $17.19M | $16.65M | $13.74M | $8.89M | |
| -$17.19M | -$16.65M | -$13.74M | -$8.89M | |
| — | $200K | — | $147K | |
| $168K | $247K | $251K | — | |
| — | -$2M | $32K | -$213K | |
| — | $0 | $0 | $0 | |
| -$18.68M | -$18.65M | -$11.16M | -$16.49M | |
| -$13.22M | — | -$11.16M | -$19.06M | |
| USD/shares | — | -$8.40 | -$6.80 | -$13.60 |
| USD/shares | — | -$8.40 | -$6.80 | -$13.60 |
| shares | — | 2.23M | 1.64M | 1.41M |
| shares | — | 2.23M | 1.64M | 1.41M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.75×
EV/EBIT
—
Biotechnology median 26.36×
P/E (TTM)
—
Biotechnology median 7.37×